Investigational Drug Details
| Drug ID: | D118 |
| Drug Name: | Ampicillin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00415 |
| DrugBank Description: | Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. |
| PubChem ID: | 6249 |
| CasNo: | 69-53-4 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O |
| Structure: |
|
| InChiKey: | AVKUERGKIZMTKX-NJBDSQKTSA-N |
| Molecular Weight: | 349.405 |
| DrugBank Targets: | Penicillin-binding protein 2a; Penicillin-binding protein 1b; Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Solute carrier family 15 member 1; Solute carrier family 15 member 2; Angiopoietin-1 receptor |
| DrugBank MoA: | By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor. |
| DrugBank Pharmacology: | Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. |
| DrugBank Indication: | For treatment of infection (Respiratory, GI, UTI and meningitis) due to E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella, nonpenicillinase-producing N. gononhoeae, H. influenzae, staphylococci, streptococci including streptoc |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|